// App-Quantinova.ai

1172 : Levodopa responsiveness in Parkinson’s disease is significantly impaired in those with diabetes and increased vascular risk.

Researchers

Presenter

  • N. Malek

Principal Investigators

  • M. Lawton

  • K. Grosset

  • N. Bajaj

  • R. Barker

  • Y. Ben-Shlomo

  • D. Burn

  • T. Foltynie

  • J. Hardy

  • H. Morris

  • N. Williams

  • N. Wood

  • D. Grosset

Medical Centers

  • N/A

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Endocrine/metabolic Diseases (ME)

Disease

  • Parkinson's disease

  • Diabetes

Biomarkers

  • Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Epsilon

Drug/Treatment

  • Levodopa

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved